YM BioSciences reports 2005 year end operational and financial results MISSISSAUGA, Sept. 12 /CNW/ - YM BioSciences Inc. (AMEX:YMI, TSX:YM...
YM BioSciences to present results of Norelin(TM) study at Cancer Vaccines/Adjuvants/Delivery 2005 Congress in Lisbon MISSISSAUGA, ON, Sept. 5...
YM Biosciences' subsidiary DELEX Therapeutics to initiate Phase IIb trial for the treatment of acute pain with AeroLEF(TM) MISSISSAUGA, ON, Aug...
YM BioSciences to Initiate Non-Small-Cell Lung Cancer Trial with Nimotuzumab - Company expands target indications for its anti-EGF receptor...
YM BioSciences expands anti-cancer product pipeline - Company licenses portfolio of drugs that may enhance chemotherapies - MISSISSAUGA, ON, Aug...
YM BioSciences expands development program for EGFR inhibitor nimotuzumab - YM Partners with Kuhnil Pharmaceutical Co. to Develop Nimotuzumab...
YM BioSciences achieves primary objective with Norelin(TM) study MISSISSAUGA, ON, May 25 /CNW/ - YM BioSciences Inc. (AMEX:YMI, TSX:YM...
YM BioSciences and CIMAB achieve clinical milestone - Data for TheraCIM h-R3 in High Grade Malignant Glioma presented at ASCO 2005 - - Clinical...
YM BioSciences survival analysis data published at ASCO MISSISSAUGA, ON, May 19 /CNW/ - YM BioSciences Inc. (AMEX:YMI, TSX:YM, AIM:YMBA), the...
YM BioSciences reports third quarter 2005 operational and financial results MISSISSAUGA, ON, May 12 /CNW/ - YM BioSciences Inc. (AMEX:YMI, TSX:YM...
YM BioSciences completes acquisition of DELEX MISSISSAUGA, ON, May 3 /CNW/ - YM BioSciences Inc. (AMEX:YMI, TSX:YM, AIM:YMBA), the cancer product...
YM BioSciences to acquire DELEX Therapeutics - Acquisition provides YM with third late-stage drug for the cancer market - MISSISSAUGA, ON, April...
YM BioSciences' TheraCIM receives investigator sponsored IND from FDA - TheraCIM h-R3 (nimotuzumab) to treat child with brain cancer under...
YM BioSciences' TheraCIM receives IND YM BioSciences' TheraCIM receives investigator sponsored IND from FDA - TheraCIM h-R3 (nimotuzumab) to...
YM BioSciences and Oncoscience Report Response Rate of 35.3% in Pediatric Glioma - TheraCIM h-R3 (nimotuzumab) Phase II Results Presented at...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.